For Manuscript Submission, Check or Review Login please go to Submission Websites List.
For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.
Pilot Study of Elevated Levels of Insulin-Like Growth Factor-Binding Protein-2 as Indicators of Hepatocellular CarcinomaRanke M.B.a · Maier K.-P.b · Schweizer R.a · Stadler B.b · Schleicher S.c · Elmlinger M.a · Flehmig B.c
aPaediatric Endocrinology Section, University Children’s Hospital, Tübingen, bDepartment of Gastroenterology, Städtische Kliniken, Esslingen, and cDepartment of Virology, University Children’s Hospital, Tübingen, Germany
Background/Aims: Insulin-like growth factor-binding protein-2 (IGFBP-2) is expressed in many malignant tissues, and elevated serum levels can be indicators of tumour activity in addition to conventional tumour markers. Our aim was to evaluate the role of IGFBP-2 levels together with insulin-like growth factor (IGF)-I, IGF-II and IGFBP-3 in the diagnostic work-up of patients with hepatocellular carcinoma (HCC). Methods: In 50 (39 males, 11 females) histologically confirmed and TNM-graded patients with HCC who had not received adjuvant chemotherapy, the basal serum levels of IGF-I, IGF-II, IGFBP-3, IGFBP-2 and α-fetoprotein (AFP) were measured. The median age of the patients was 66 (37–84) years, body mass index was normal (25 (35–16) kg/m2). Results: The levels of IGF-I, IGF-II and IGFBP-3 were diminished, as is the case when nutrition, hepatic function and growth hormone (GH) secretion are decreased. The levels of AFP and IGFBP-2 were markedly high. In 37 cases, IGFBP-2 levels were above the age-related norm, and in 40 cases AFP levels were also elevated. In 3 cases, both AFP and IGFBP-3 were normal, and in 4 cases AFP was high but IGFBP-2 normal, whereas in 10 cases AFP was normal but IGFBP-2 was high. Conclusions: In addition to AFP, IGFBP-2 appears to be a suitable marker for the evaluation of the serological status of HCC patients. A longitudinal study during disease management is required to assess the full potential of IGFBP-2 measurements as a marker.
© 2003 S. Karger AG, Basel